AR117228A1 - DERIVADOS DE PIRAZOLO[1,2-a]PIRIDINA, 1H-BENZO[d][1,2,3]TRIAZOL, IMIDAZOPIRIMIDINA Y BENCIMIDAZOL PARA USAR EN EL TRATAMIENTO DE LA INFECCIÓN POR ARENAVIRUS - Google Patents

DERIVADOS DE PIRAZOLO[1,2-a]PIRIDINA, 1H-BENZO[d][1,2,3]TRIAZOL, IMIDAZOPIRIMIDINA Y BENCIMIDAZOL PARA USAR EN EL TRATAMIENTO DE LA INFECCIÓN POR ARENAVIRUS

Info

Publication number
AR117228A1
AR117228A1 ARP190103517A ARP190103517A AR117228A1 AR 117228 A1 AR117228 A1 AR 117228A1 AR P190103517 A ARP190103517 A AR P190103517A AR P190103517 A ARP190103517 A AR P190103517A AR 117228 A1 AR117228 A1 AR 117228A1
Authority
AR
Argentina
Prior art keywords
independently selected
alkyl
nhr10
halogen
treatment
Prior art date
Application number
ARP190103517A
Other languages
English (en)
Inventor
Kenneth Mcormack
Gregory Henkel
Michael Bruno Plewe
Vidyasagar Reddy Gantla
Nadezda Sokolova
Eric Brown
Original Assignee
Arisan Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arisan Therapeutics filed Critical Arisan Therapeutics
Publication of AR117228A1 publication Critical patent/AR117228A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos heterocíclicos utilizables en el tratamiento de infecciones por arenavirus e infecciones víricas mediadas por glicoproteínas de arenavirus. Reivindicación 1: Un compuesto de fórmula estructural (1), o una sal farmacéuticamente aceptable y un portador, diluyente o vehículo farmacéuticamente aceptable del mismo, en donde A se selecciona independientemente entre C y N; G se selecciona independientemente entre CH, CD y N; E se selecciona independientemente entre CH, CD y N; J se selecciona independientemente entre los restos de fórmula (2) y (3); R² se selecciona independientemente entre H, D, -OR³, -R⁴, -NHR¹⁰, -CONHR¹⁰; R³ se selecciona independientemente entre H, D, alquilo C₁₋₆, alquenilo C₂₋₆, -NHC(O)R⁴, -C(O)NHR¹⁰ y -C(O)R¹⁰, en donde cada alquilo C₁₋₆ está opcionalmente sustituido con D, halógeno, -OH, -OR⁴, -NHR¹⁰; R⁴ se selecciona independientemente entre alquilo C₁₋₆ y cicloheteroalquilo C₂₋₉ opcionalmente sustituido con D, halógeno, -OH, -OR¹⁰ y NHR¹⁰; R⁵ se selecciona independientemente entre H, D, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, halógeno, -OR³, -CO₂R¹⁰, -NHC(O)R⁴, -C(O)NHR¹⁰, -NHR¹⁰, -CHNHR¹⁰, -CN, -CR⁴ y -C(O)R¹⁰, en donde cada alquilo C₁₋₆ está opcionalmente sustituido con D; R⁶ se selecciona independientemente entre H, D, halógeno, -OR³ y R⁴; R⁹ se selecciona independientemente entre H, D, halógeno, -OR¹⁰ y alquilo C₁₋₆; R¹⁰ se selecciona independientemente entre H, D, -OH, alquilo C₁₋₆ y alquenilo C₂₋₆; y cuando E es N, CH o CD, entonces A es C, G es CH o CD y J es el resto de fórmula (2); y cuando A es N, entonces J es el resto de fórmula (3); con la condición de que se excluyan los compuestos: seleccionados del grupo de fórmulas (4).
ARP190103517A 2018-12-06 2019-12-02 DERIVADOS DE PIRAZOLO[1,2-a]PIRIDINA, 1H-BENZO[d][1,2,3]TRIAZOL, IMIDAZOPIRIMIDINA Y BENCIMIDAZOL PARA USAR EN EL TRATAMIENTO DE LA INFECCIÓN POR ARENAVIRUS AR117228A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862776390P 2018-12-06 2018-12-06

Publications (1)

Publication Number Publication Date
AR117228A1 true AR117228A1 (es) 2021-07-21

Family

ID=70975517

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103517A AR117228A1 (es) 2018-12-06 2019-12-02 DERIVADOS DE PIRAZOLO[1,2-a]PIRIDINA, 1H-BENZO[d][1,2,3]TRIAZOL, IMIDAZOPIRIMIDINA Y BENCIMIDAZOL PARA USAR EN EL TRATAMIENTO DE LA INFECCIÓN POR ARENAVIRUS

Country Status (11)

Country Link
EP (1) EP3890731A4 (es)
JP (1) JP2022509763A (es)
KR (1) KR20210106997A (es)
CN (1) CN113329750A (es)
AR (1) AR117228A1 (es)
AU (1) AU2019393784A1 (es)
BR (1) BR112021010909A2 (es)
CA (1) CA3118765A1 (es)
EA (1) EA202191001A1 (es)
MX (1) MX2021005234A (es)
WO (1) WO2020117794A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE372966T1 (de) * 1994-03-25 2007-09-15 Isotechnika Inc Verbesserung der effektivität von arzneimitteln duren deuterierung
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
CN104507473A (zh) * 2012-02-17 2015-04-08 奇尼塔四有限责任公司 用于治疗沙粒病毒感染的抗病毒药物
US11352328B2 (en) * 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus

Also Published As

Publication number Publication date
EP3890731A1 (en) 2021-10-13
EA202191001A1 (ru) 2021-08-16
BR112021010909A2 (pt) 2021-08-24
MX2021005234A (es) 2021-08-11
CN113329750A (zh) 2021-08-31
AU2019393784A1 (en) 2021-05-27
CA3118765A1 (en) 2020-06-11
JP2022509763A (ja) 2022-01-24
WO2020117794A1 (en) 2020-06-11
KR20210106997A (ko) 2021-08-31
EP3890731A4 (en) 2022-08-17

Similar Documents

Publication Publication Date Title
AR108710A1 (es) Compuestos modulares de fxr (nr1h4)
PE20230376A1 (es) Compuestos moduladores de la diacilglicerol quinasa
AR127309A2 (es) Derivados de piridazinona
AR106037A1 (es) Moduladores de la proteína core de la hepatitis b
AR095430A1 (es) Compuestos de pirimidina y piridina y su uso como inhibidores de la actividad de fgfr
AR114793A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos
AR115296A1 (es) Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer
AR111594A1 (es) Agentes inhibidores de la tirosina quinasa de bruton
AR108175A1 (es) Compuestos antivíricos de tiazol acetamida
AR123355A1 (es) Inhibidores de apol1 y métodos para usar los mismos
AR111814A1 (es) Compuestos de formimidamida útiles contra microorganismos fitopatógenos
AR121777A1 (es) Derivados de diamina macrocíclica como inhibidores de ent para el tratamiento de cánceres, y combinación de estos con antagonistas del receptor de adenosina
PE20081113A1 (es) Inhibidores virales policiclicos
AR120556A1 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
AR108845A1 (es) Derivados de [1,2,3]triazolo[4,5-d]pirimidina como moduladores del receptor cb2
AR108327A1 (es) Compuestos pirimidinona fusionados sustituidos
AR117228A1 (es) DERIVADOS DE PIRAZOLO[1,2-a]PIRIDINA, 1H-BENZO[d][1,2,3]TRIAZOL, IMIDAZOPIRIMIDINA Y BENCIMIDAZOL PARA USAR EN EL TRATAMIENTO DE LA INFECCIÓN POR ARENAVIRUS
AR111826A1 (es) Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias
AR122336A1 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
AR041720A1 (es) Derivados de n- benzodioxolilo, n- benzodioxanilo y n- benzodioxepinilarilcarboxamida que pueden usarse para el tratamiento de dislipidemia, y composiciones farmaceuticas que los contienen
AR126733A1 (es) Inhibidores de nicotinamida ripk1
AR118471A1 (es) Derivados de pirrol e imidazol fusionados con piridina como inhibidores de ripk2
AR110252A1 (es) Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
AR126754A1 (es) Compuestos heterocíclicos y métodos de uso
AR114182A1 (es) Inhibidores cardíacos de sarcómero